Fagron reports 16% increase in revenue to € 156.4 million
14 Avril 2022 - 7:00AM
Fagron reports 16% increase in revenue to € 156.4 million
Regulated informationNazareth (Belgium)/Rotterdam (The
Netherlands), 14 April 2022 – 7.00 AM CET
Fagron reports 16% increase in revenue to € 156.4
million
Fagron, the leading global player in pharmaceutical compounding,
today publishes its quarterly results for the period ending 31
March 2022.
Highlights
- Strong top line growth despite challenging operating
environment
- Revenue increased by 16.0% to € 156.4 million (10.2% at
constant exchange rates), with growth across all regions
- Organic growth of 13.3% (7.6% at constant exchange rates)
- Navigating ongoing supply chain disruptions and
risks
- Lingering pressure on supply chain due to COVID related issues
with limited direct impact from Ukraine crisis thus far
- Inventory management and cost efficiency key focus areas to
maximize product availability with centralized procurement
team
- Continued rollout of disciplined acquisition
strategy
- Acquisition of Hiperscan in Germany and Curaphar in the
Netherlands further strengthens position in key markets
- Letco acquisition and simultaneous divestment of 80% of
contract manufacturing division in North America
- Pharma-Pack acquisition in Belgium
- Further progress on environmental and social
initiatives
- Installed 1,000 solar panels
- Launched the global female Fagron mentoring program
- Reporting on Compounding Services and Premium
Pharmaceuticals consolidated
Rafael Padilla, CEO of Fagron:
“We have delivered robust results in the first quarter of 2022
through organic growth and M&A activities even though we are in
the midst of an unpredictable operating environment given the
lingering impact from COVID, ongoing supply chain challenges as
well as rising inflation.
In line with our disciplined acquisition strategy, we completed
three acquisitions in the first quarter of this year with a view to
solidifying our position in key European markets. We also
strengthened our position in North America with the acquisition of
Letco, the integration of which is progressing as planned. We
remain committed to further consolidating the market and adding
capabilities to Fagron through a rigorous assessment of market
opportunities.
Supported by the favorable underlying secular trends from
increased personalization and healthcare focus globally, we remain
committed to our strategic priorities and feel confident in our
ability to deliver to our mid-term targets, despite the current
challenging environment.”
Please open the link below for the press release:
Fagron reports 16% increase in revenue to € 156.4 million
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Fagron NV (EU:FAGR)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024